AQR Capital Management LLC decreased its holdings in Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 14.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,417 shares of the biotechnology company’s stock after selling 9,544 shares during the period. AQR Capital Management LLC owned about 0.08% of Veracyte worth $1,266,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Veracyte by 3.7% in the first quarter. Vanguard Group Inc. now owns 7,384,871 shares of the biotechnology company’s stock worth $163,649,000 after purchasing an additional 266,660 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Veracyte by 7.8% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,347,436 shares of the biotechnology company’s stock valued at $74,179,000 after buying an additional 242,760 shares during the last quarter. Granahan Investment Management LLC grew its holdings in shares of Veracyte by 32.1% during the fourth quarter. Granahan Investment Management LLC now owns 503,898 shares of the biotechnology company’s stock valued at $13,862,000 after buying an additional 122,574 shares during the last quarter. Bamco Inc. NY grew its holdings in shares of Veracyte by 46.3% during the first quarter. Bamco Inc. NY now owns 1,115,806 shares of the biotechnology company’s stock valued at $24,726,000 after buying an additional 353,000 shares during the last quarter. Finally, Nordea Investment Management AB boosted its holdings in Veracyte by 232.3% in the first quarter. Nordea Investment Management AB now owns 272,176 shares of the biotechnology company’s stock valued at $6,050,000 after purchasing an additional 190,262 shares during the last quarter.
Insider Buying and Selling
In related news, insider John Leite sold 1,277 shares of the stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $25.00, for a total transaction of $31,925.00. Following the completion of the transaction, the insider now owns 82,968 shares of the company’s stock, valued at approximately $2,074,200. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Veracyte news, insider John Leite sold 1,277 shares of the stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $25.00, for a total transaction of $31,925.00. Following the sale, the insider now directly owns 82,968 shares in the company, valued at $2,074,200. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Evan/ Fa Jones sold 20,457 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $32.20, for a total transaction of $658,715.40. Following the sale, the director now owns 34,343 shares in the company, valued at approximately $1,105,844.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 45,918 shares of company stock valued at $1,399,541. Company insiders own 1.30% of the company’s stock.
Wall Street Analyst Weigh In
Read Our Latest Stock Analysis on Veracyte
Veracyte Trading Up 1.1 %
VCYT stock opened at $32.27 on Friday. The firm has a 50-day moving average of $31.38 and a two-hundred day moving average of $24.95. Veracyte, Inc. has a 12 month low of $18.61 and a 12 month high of $35.51. The company has a market cap of $2.47 billion, a price-to-earnings ratio of -34.33 and a beta of 1.67.
Veracyte (NASDAQ:VCYT – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.10. Veracyte had a negative net margin of 13.52% and a positive return on equity of 1.52%. The business had revenue of $114.43 million during the quarter, compared to analysts’ expectations of $100.27 million. During the same quarter in the prior year, the company posted ($0.12) EPS. The business’s revenue for the quarter was up 26.7% on a year-over-year basis. As a group, equities analysts forecast that Veracyte, Inc. will post 0.16 earnings per share for the current year.
About Veracyte
Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.
Featured Articles
- Five stocks we like better than Veracyte
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Top Stocks Investing in 5G Technology
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- What is a Dividend King?
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT – Free Report).
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.